Clotrimazole as a pharmaceutical: Past, present and future

Journal of Applied Microbiology

Volumn 117, Issue 3, 2014, Pages 611-617

  Crowley, P D ^a   Gallagher, H C ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antifungals; Antimicrobials; Formulation; Mycology; Pharmaceuticals; Pharmaceutics; Pharmacology; Resistance

Indexed keywords

BIOCHEMISTRY; DISEASES; DRUG PRODUCTS; DRUG THERAPY;

ANTIFUNGALS; ANTIMICROBIAL; ANTIMYCOTICS; BROAD SPECTRUM; CANDIDA ALBICANS; FORMULATION; FUNGAL INFECTION; PHARMACEUTIC; PHARMACOLOGY; RESISTANCE;

FUNGI;

CLOTRIMAZOLE; ANTIFUNGAL AGENT;

ALCOHOL; ANTIMICROBIAL ACTIVITY; CANCER; CELL ORGANELLE; DISEASE RESISTANCE; DISEASE TREATMENT; DRUG RESISTANCE; FUNGAL DISEASE; MOLECULAR ANALYSIS; STEROL;

ANTIMICROBIAL ACTIVITY; CHEMICAL STRUCTURE; DRUG DOSAGE FORM; HUMAN; HYPERTRANSAMINASEMIA; MEDICINAL CHEMISTRY; NAUSEA; PRURITUS; REVIEW; SIDE EFFECT; UNPLEASANT MOUTH SENSATION; UNPLEASANT SENSATION; VOMITING;

CANDIDA ALBICANS; TINEA PEDIS;

ANTIFUNGAL AGENTS; CLOTRIMAZOLE;

EID: 85027954272     PISSN: 13645072     EISSN: 13652672     Source Type: Journal    
DOI: 10.1111/jam.12554     Document Type: Review

References (53)

1. Alsterholm, M., Karami, N. and Faergemann, J. (2010) Antimicrobial activity of topical skin pharmaceuticals - an in vitro study. Acta Derm Venereol 90, 239-245.
2. Bartolommei, G., Tadini-Buoninsegni, F., Hua, S., Moncelli, M.R., Inesi, G. and Guidelli, R. (2006) Clotrimazole inhibits the Ca2+-ATPase (SERCA) by interfering with Ca2+ binding and favoring the E2 conformation. J Biol Chem 281, 9547-9551.
3. Benzaquen, L.R., Brugnara, C., Byers, H.R., Gattoni-Celli, S. and Halperin, J.A. (1995) Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat Med 1, 534-540.
4. Bilensoy, E., Rouf, M., Vural, I. and Hincal, A. (2006) Thermosensitive vaginal gel formulation for the controlled release of clotrimazole via complexation to beta-cyclodextrin. J Control Release 116, e107-e109.
5. Brugnara, C. and De Franceschi, L. (2006) Clinical trials of new therapeutic pharmacology for sickle cell disease. Sante 16, 263-268.
6. Brugnara, C., Gee, B., Armsby, C.C., Kurth, S., Sakamoto, M., Rifai, N., Alper, S.L. and Platt, O.S. (1996) Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 97, 1227-1234.
7. Costa, C., Nunes, J., Henriques, A., Mira, N.P., Nakayama, H., Chibana, H. and Teixeira, M.C. (2014) Candida glabrata drug: H+ antiporter CgTpo3 (ORF CAGL0I10384g): role in azole drug resistance and polyamine homeostasis. J Antimicrob Chemother. doi:10.1093/jac/dku1044. [Epub ahead of print].
8. Cudmore, S.L., Delgaty, K.L., Hayward-McClelland, S.F., Petrin, D.P. and Garber, G.E. (2004) Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis. Clin Microbiol Rev 17, 783-793.
9. Eaton, D.R. and Wilkins, R.G. (1978) Reduction by dithionite ion of adducts of metmyoglobin with imidazole, pyridine, and derivatives. J Biol Chem 253, 908-915.
10. Eaton, D. and Wilson, K. (1979) Reaction of imidazole and hydroquinone with oxymyoglobin. J Inorg Biochem 10, 195-203.
11. Eliel, E.L., Wilen, S.H. and Mander, L.N.(eds) (1994). Stereochemistry of organic compounds. p. 381. New York: John Wiley and Sons.
12. Ellepola, A. and Samaranayake, L. (2000) Oral candidal infections and antimycotics. Crit Rev Oral Biol Med 11, 172-198.
13. Gbotosho, O.T., Cytlak, U.M., Hannemann, A., Rees, D.C., Tewari, S. and Gibson, J.S. (2013) Inhibitors of second messenger pathways and Ca-induced exposure of phosphatidylserine in red blood cells of patients with sickle cell disease. Pflugers Arch. doi:10.1007/s00424-00013-01343-00428. [Epub ahead of print].
14. Gelone, S.A. and O'Donnell, J. (2006) Anti infectives. In Remington the science and practice of pharmacy, 21st Edition ed. Troy, D.B., pp. 1626-1684. Baltimore: Lippincott Williams and Wilkins.
15. Gemma, S., Campiani, G., Butini, S., Kukreja, G., Joshi, B.P., Persico, M., Catalanotti, B., Novellino, E. et al. (2007) Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore. J Med Chem 50, 595-598.
16. Gemma, S., Campiani, G., Butini, S., Kukreja, G., Coccone, S.S., Joshi, B.P., Persico, M., Nacci, V. et al. (2008) Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies. J Med Chem 51, 1278-1294.
17. Hicks, R.G. (2007) What's new in stable radical chemistry? Org Biomol Chem 5, 1321-1338.
18. Hitchcock, C.A., Dickinson, K., Brown, S., Evans, E. and Adams, D. (1990) Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans. Biochem J 266, 475-480.
19. 2+ signaling in Madin Darby canine kidney cells. Life Sci 66, 2289-2296.
20. Kalb, R. and Grossman, M. (1985) Contact dermatitis to clotrimazole. Cutis 36, 240-242.
21. Lorand, T. and Kocsis, B. (2007) Recent advances in antifungal agents. Mini-Rev Med Chem 7, 900-911.
22. Malani, A.N. and Kauffman, C.A. (2007) Changing epidemiology of rare mould infections. Drugs 67, 1803-1812.
23. Marichal, P., Gorrens, J. and Coene, M. (1990) Biochemical basis for the activity and selectivity of oral antifungal drugs. Br J Clin Pract Suppl 71, 41-46.
24. Mishra, N., Prasad, T., Sharma, N., Payasi, A., Prasad, R., Gupta, D. and Singh, R. (2007) Pathogenicity and drug resistance in Candida albicans and other yeast species. Acta Microbiol Immunol Hung 54, 201-235.
25. Navarro, M., Peña, N.P., Colmenares, I., González, T., Arsenak, M. and Taylor, P. (2006) Synthesis and characterization of new palladium-clotrimazole and palladium-chloroquine complexes showing cytotoxicity for tumor cell lines in vitro. J Inorg Biochem 100, 152-157.
26. Navarro, M., Higuera-Padilla, A.R., Arsenak, M. and Taylor, P. (2009) Synthesis, characterization, DNA interaction studies and anticancer activity of platinum-clotrimazole complexes. Transition Met Chem 34, 869-875.
27. Navas, J.M., Chana, A., Herradón, B. and Segner, H. (2004) Induction of cytochrome P4501A (CYP1A) by clotrimazole, a non-planar aromatic compound. Computational studies on structural features of clotrimazole and related imidazole derivatives. Life Sci 76, 699-714.
28. Odds, F.C., Brown, A.J. and Gow, N.A. (2003) Antifungal agents: mechanisms of action. Trends Microbiol 11, 272-279.
29. OSPAR Commission (2005) Hazardous Substance Series: Open background documentation on clotrimazole, publication no 2005/199. Available at: http://www.ospar.org/documents/dbase/publications/p00199/p00199_bd%20on%20clotrimazole.pdf. (accessed 10 June 2014).
30. Oyama, T.M., Oyama, T.B., Oyama, K., Matsui, H., Horimoto, K., Nishimura, Y. and Oyama, Y. (2006) Clotrimazole, an antifungal drug possessing diverse actions, increases the vulnerability to cadmium in lymphocytes dissociated from rat thymus. Toxicology 228, 269-279.
31. Pasqualotto, A.C., Thiele, K.O. and Goldani, L.Z. (2010) Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Curr Opin Investig Drugs, 11, 165-174.
32. Pelletier, R., Peter, J., Antin, C., Gonzalez, C., Wood, L. and Walsh, T.J. (2000) Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations. J Clin Microbiol 38, 1563-1568.
33. Podust, L.M., Poulos, T.L. and Waterman, M.R. (2001) Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci 98, 3068-3073.
34. Porsbring, T., Blanck, H., Tjellström, H. and Backhaus, T. (2009) The pharmaceutical clotrimazole affects marine microalgal communities at picomolar concentrations. In SETAC Europe 19th Annual Meeting, Gothenburg, Sweden. http://swepubkbse/bib/swepub:oai:servicessciglooorg:113304?tab2=abs&language=en.
35. Rittenhouse, A., Vandorpe, D., Brugnara, C. and Alper, S. (1997) The antifungal imidazole clotrimazole and its major in vivo metabolite are potent blockers of the calcium-activated potassium channel in murine erythroleukemia cells. J Membr Biol 157, 177-191.
36. Robles-Escajeda, E., Martínez, A., Varela-Ramirez, A., Sánchez-Delgado, R.A. and Aguilera, R.J. (2013) Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells. Cell Biol Toxicol 29, 431-443.
37. Santos, S.S., Lorenzoni, A., Pegoraro, N.S., Denardi, L.B., Alves, S.H., Schaffazick, S.R. and Cruz, L. (2014) Formulation and in vitro evaluation of coconut oil-core cationic nanocapsules intended for vaginal delivery of clotrimazole. Colloids Surf B Biointerfaces 116c, 270-276.
38. Shah, M., Miscony, Z., Javadzadeh-Tabatabaie, M., Ganellin, C. and Haylett, D. (2001) Clotrimazole analogues: effective blockers of the slow afterhyperpolarization in cultured rat hippocampal pyramidal neurones. Br J Pharmacol 132, 889-898.
39. Singh, S., Jain, S., Muthu, M., Tiwari, S. and Tilak, R. (2008) Preparation and evaluation of buccal bioadhesive films containing clotrimazole. AAPS PharmSciTech 9, 660-667.
40. Sobel, J.D. (2007) Vulvovaginal candidosis. Lancet 369, 1961-1971.
41. Song, H. and Shin, H.-S. (1998) The antifungal drug clotrimazole. Acta Crystallogr Sect C: Cryst Struct Commun 54, 1675-1677.
42. Sweetman, S.C.(eds) (2007). Martindale: the complete drug reference. p. 764. London: Pharmaceutical Press.
43. Thapa, D., Lee, J.S., Park, M.-A., Cho, M.-Y., Park, Y.-J., Choi, H.G., Jeong, T.C. and Kim, J.-A. (2009) Inhibitory effects of clotrimazole on TNF-α-induced adhesion molecule expression and angiogenesis. Arch Pharm Res 32, 593-603.
44. Tian, M., Dong, M.Q., Chiu, S.W., Lau, C.P. and Li, G.R. (2006) Effects of the antifungal antibiotic clotrimazole on human cardiac repolarization potassium currents. Br J Pharmacol 147, 289-297.
45. Tiffert, T., Ginsburg, H., Krugliak, M., Elford, B.C. and Lew, V.L. (2000) Potent antimalarial activity of clotrimazole in in vitro cultures of Plasmodium falciparum. Proc Natl Acad Sci 97, 331-336.
46. Tonglairoum, P., Ngawhirunpat, T., Rojanarata, T., Kaomongkolgit, R. and Opanasopit, P. (2014) Fast-acting clotrimazole composited PVP/HPbetaCD nanofibers for oral candidiasis application. Pharm Res. doi:10.1007/s11095-11013-11291-11091. [Epub ahead of print].
47. Trivedi, V., Chand, P., Srivastava, K., Puri, S.K., Maulik, P.R. and Bandyopadhyay, U. (2005) Clotrimazole inhibits hemoperoxidase of Plasmodium falciparum and induces oxidative stress. Proposed antimalarial mechanism of clotrimazole. J Biol Chem 280, 41129-41136.
48. Valerio, C., Perillo, T., Brescia, L. and Russo, F. (2013) Antifungal agents in current pediatric practice. Curr Infect Dis Rep 15, 278-287.
49. Vanić, Ž. and Škalko-Basnet, N. (2013) Nanopharmaceuticals for improved topical vaginal therapy: can they deliver? Eur J Pharm Sci 50, 29-41.
50. Weig, M. and Brown, A.J. (2007) Genomics and the development of new diagnostics and anti-Candida drugs. Trends Microbiol 15, 310-317.
51. White, T.C., Holleman, S., Dy, F., Mirels, L.F. and Stevens, D.A. (2002) Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46, 1704-1713.
52. 3 cells. Neuropharmacology 38, 979-989.
53. Chemical Drawing package used: MarvinSketch ver. 4.1.13. for Macintosh Downloadable from www.chemaxon.com.